Immutep (ASX: IMM) Hits Key Phase III Milestone: Buy the Dip or Take Profits Before the Critical Data Readout?

Immutep (ASX: IMM) has pulled back roughly 22 per cent from its recent 52-week high near A$0.46, settling around A$0.36 this week. The selloff comes despite no change to the company’s clinical outlook and follows a strong rally that began in early December after Immutep signed a landmark licensing deal with Dr Reddy’s Laboratories.

What makes the timing interesting is that Immutep just confirmed it has enrolled 378 patients in its Phase III TACTI-004 trial, hitting the halfway mark of its roughly 756-patient target. The trial is running across more than 140 sites in 27 countries, and an independent committee is expected to conduct a critical interim analysis in the coming weeks to assess whether the treatment is showing enough efficacy to continue. For investors, the pullback raises a key question: Is this a chance to buy ahead of a potentially transformative data readout, or is it time to lock in gains before the outcome is known?

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

Efti’s Opportunity in a US$24 Billion Lung Cancer Market

Immutep’s lead drug, eftilagimod alfa (efti), is being developed to treat non-small cell lung cancer (NSCLC), the deadliest cancer globally, with more than two million new cases every year. The global NSCLC treatment market is estimated at roughly US$24 billion.

The current standard of care combines Merck’s KEYTRUDA with chemotherapy. However, this approach works poorly for patients with low or no PD-L1 expression, a protein used to predict immunotherapy response. These harder-to-treat patients represent approximately two-thirds of all NSCLC cases.

This is where efti stands apart. Results from the INSIGHT-003 trial, presented at ESMO 2025, showed that combining efti with KEYTRUDA and chemotherapy produced a 61.7 per cent response rate in patients with low or no PD-L1, well above the 40.8 per cent historical benchmark. Disease control rates ranged between 86 per cent and 100 per cent across all PD-L1 levels, and the U.S. FDA has granted efti Fast Track designation for first-line NSCLC treatment.

We believe efti’s ability to improve outcomes regardless of PD-L1 levels is its strongest differentiator. If the Phase III confirms these earlier results, Efti could become a new standard of care for a very large group of lung cancer patients.

Dr Reddy’s Deal and Cash Runway Remove Near-Term Funding Risk

One of the biggest risks for clinical-stage biotechs is running out of cash before key data arrives. Immutep has effectively taken that concern off the table.

In December 2025, the company signed a licensing deal with Dr Reddy’s Laboratories for emerging markets, delivering an upfront payment of approximately A$30 million received in January 2026, with up to A$528 million in potential milestone payments plus double-digit royalties on future sales. This deal does more than fund operations. It signals a major pharmaceutical company has done its own due diligence on Efti and sees enough commercial potential to commit meaningful capital.

Combined with A$99.1 million in existing cash at 31 December 2025, Immutep’s pro-forma position now sits at approximately A$129 million, extending its runway well into mid-2027. For investors, this means no imminent dilution risk and enough funding to reach the interim data readout and beyond.

The Investor’s Takeaway – Buy, Wait, or Take Profits?

The bull case has strengthened since the pullback. Analyst consensus targets sit around A$1.30, implying more than 260 per cent upside from the current A$0.36. If the interim analysis delivers a positive result in the coming weeks, the stock could re-rate significantly as the market begins pricing in a genuine shot at regulatory approval.

The bear case is equally clear: this is a binary event. If the independent data monitoring committee determines the trial is unlikely to succeed, the stock would take a sharp hit. Phase III failures in oncology are not uncommon, and earlier-stage data do not guarantee a positive outcome.

We believe the risk-reward is compelling for investors willing to accept binary risk. However, position sizing matters. Given the all-or-nothing nature of the interim data, spreading exposure rather than going all-in seems prudent. Conservative investors may prefer to wait for the readout before taking a position, even if that means paying a higher price for greater certainty.